about
sameAs
An integrative genomic and proteomic approach to chemosensitivity predictionA population-based gene signature is predictive of breast cancer survival and chemoresponseHybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse predictionUsing drug response data to identify molecular effectors, and molecular "omic" data to identify candidate drugs in cancerReverse phase protein microarrays advance to use in clinical trialsPharmacogenomic discovery using cell-based modelsIntegrated DNA Copy Number and Gene Expression Regulatory Network Analysis of Non-small Cell Lung Cancer MetastasisUsing expression and genotype to predict drug response in yeastSpatial normalization of reverse phase protein array data.A modular approach for integrative analysis of large-scale gene-expression and drug-response data.Data mining the NCI60 to predict generalized cytotoxicity.Gene expression patterns within cell lines are predictive of chemosensitivity.Two lung masses with different responses to pemetrexed.Early response evaluation and prediction in neoadjuvant-treated patients with esophageal cancer.Systematically characterizing and prioritizing chemosensitivity related gene based on Gene Ontology and protein interaction network.The use of genomic information to optimize cancer chemotherapyPrediction of individual response to anticancer therapy: historical and future perspectivesImproving Drug Sensitivity Prediction Using Different Types of DataHaptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis.Chamaejasmin B exerts anti-MDR effect in vitro and in vivo via initiating mitochondria-dependant intrinsic apoptosis pathway.Current dichotomy between traditional molecular biological and omic research in cancer biology and pharmacology.Computational discovery of transcription factors associated with drug response.Challenges in cancer research and multifaceted approaches for cancer biomarker quest.Proteomic methodologies and their application in colorectal cancer research.Therapeutic target database update 2014: a resource for targeted therapeutics.Metabolomic studies of human gastric cancer: reviewAn ion-current-based, comprehensive and reproducible proteomic strategy for comparative characterization of the cellular responses to novel anti-cancer agents in a prostate cell model.Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.Proteomics, genomics, and molecular biology in the personalized treatment of colorectal cancer.Comprehensive Proteome Profiling of Platelet Identified a Protein Profile Predictive of Responses to An Antiplatelet Agent Sarpogrelate.Splicing of platelet resident pre-mRNAs upon activation by physiological stimuli results in functionally relevant proteome modifications.Advances in the preclinical testing of cancer therapeutic hypotheses.
P2860
Q23909225-6EC1438C-95DA-4AD2-AC0C-84C20B876BD5Q23909226-1FCF43E9-F81D-4C5A-9131-A5F133270C7AQ23924046-8B2BC720-2E5F-4DDB-8B61-BF63BA78C8ECQ27320602-9F8041EB-3643-4AE5-B98F-12EA55E07DE3Q28384553-9A3CD42A-9505-41C5-9F3C-8495104E259AQ28392982-7C944491-DED6-440E-8036-8AA24DD20A0DQ28397049-E4B81A69-BC2C-411C-B5A9-66868DC69BF1Q28476059-E9577496-5DAD-441E-B850-2AC9CA8BF3D2Q30877911-7A653086-E708-496D-AACC-651B04D3A35DQ31154751-75F6B364-EFD6-4029-9ED8-1DDF078E193FQ31160864-A16B1AE2-199C-43EF-B0DB-68B9E531AAD8Q33318982-BF0E958A-893E-4CF7-B417-50227D8A7047Q33893971-C74AA474-41A9-4814-A55C-31075D74BBE1Q34390923-3F2D584A-31B7-4962-A8B8-BB930286C746Q34432563-FF1B43AC-346F-4EB8-8BEF-472551C71B0DQ34791981-C47EF205-EED7-42EE-8AA4-116471739244Q35024682-3B3A4106-BD1D-4C6A-AD90-8F5A367F82C9Q35179551-334A45EA-CB6B-4973-9531-878286A7C19AQ35247643-ACD9FA42-09D5-4781-907A-37F37C8753F6Q36111203-FBB048EA-BB2E-4E0C-A878-471EA6F2366FQ36363613-38B801C4-83E9-45CD-978F-DBAB64216C03Q36844885-5FCB442F-C870-4E10-A902-BEE618290AF0Q37425361-899D1E24-B8A4-402A-9003-46A4693196DEQ37643738-DD3C5F5C-F5BA-48AF-95C1-86E109480F73Q37661746-2878A412-23D7-49C7-9DBF-E78E52BC267DQ38227841-AF8A0066-9E18-4274-8399-83F9BEA2BF7FQ39277976-BA314E5A-5DD5-455F-B640-4EF331948E8AQ39308117-4D105DF2-C7DD-4119-BE8F-A0831F0BF883Q41957159-EFA1EEA3-E06B-4E3B-B242-D3791979BC0FQ42687813-566CC9A9-F26C-4928-9BB2-F828AF501CFEQ47660131-C614D41A-86D1-48A3-97AA-AE54C9D831DCQ53264472-6E6239CF-F895-49FE-9C0E-F03BE91ECB52
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Predicting cancer drug response by proteomic profiling
@nl
Predicting cancer drug response by protoeomic profiling
@ast
Predicting cancer drug response by protoeomic profiling
@en
Predicting cancer drug response by protoeomic profiling
@en-gb
type
label
Predicting cancer drug response by proteomic profiling
@nl
Predicting cancer drug response by protoeomic profiling
@ast
Predicting cancer drug response by protoeomic profiling
@en
Predicting cancer drug response by protoeomic profiling
@en-gb
prefLabel
Predicting cancer drug response by proteomic profiling
@nl
Predicting cancer drug response by protoeomic profiling
@ast
Predicting cancer drug response by protoeomic profiling
@en
Predicting cancer drug response by protoeomic profiling
@en-gb
P2093
P50
P1476
Predicting cancer drug response by protoeomic profiling
@en
P2093
P2880
P304
P356
10.1158/1078-0432.CCR-06-0290
P407
P577
2006-08-01T00:00:00Z